Patrice M Forner1, Timothy Ramacciotti2,3, John E Farey1, Reginald V Lord4,5. 1. St. Vincent's Centre for Applied Medical Research, Sydney, Australia. 2. St. Vincent's Centre for Applied Medical Research and University of New South Wales, Suite 606, 438 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia. 3. Department of Surgery, School of Medicine, University of Notre Dame, Sydney, Australia. 4. St. Vincent's Centre for Applied Medical Research and University of New South Wales, Suite 606, 438 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia. rvlord@stvincents.com.au. 5. Department of Surgery, School of Medicine, University of Notre Dame, Sydney, Australia. rvlord@stvincents.com.au.
Abstract
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopically placed device designed to achieve weight loss and improve glycemic control in obese patients. Previous studies report promising results but typically included small patient numbers and short follow-up. This study aims to determine the safety and effectiveness of the device. METHODS: Study design: A series of all patients treated by the DJBL at our institutions. OUTCOME MEASUREMENTS: Weight loss, biochemical measures, complications. RESULTS: Between July 2012 and March 2015, 114 consecutive patients were treated for a mean 51.1 weeks (standard deviation (SD) 19.9 weeks). Mean total body weight change from baseline was 12.0 kg (SD 8.5 kg, p < 0.001). Mean percent total body weight loss (%TWL) was 10.5% (SD 7.3%). Mean HbA1c was not significantly improved, but of 10 patients on insulin, 4 ceased insulin and 4 reduced insulin dosages. There was a significant decrease in hemoglobin and total cholesterol and a significant increase in serum alkaline phosphatase. Seventy-four percent of patients experienced at least one adverse event, some of them serious including 6 device obstructions, 5 gastrointestinal hemorrhages, 2 liver abscesses, and 1 acute pancreatitis. Seventy-four percent of patients experienced weight gain after removal with a mean 4.5 ± 6.1 kg (p < 0.0001) within the first 6 months after explantation. CONCLUSIONS: The DJBL provides significant but highly variable weight loss. Glycemic control was variable. Most insulin-requiring T2DM patients ceased or reduced insulin. Most patients experience an adverse event and most regain significant weight after device removal. Major adverse events can occur, including the potentially life-threatening complications of hepatic abscess and gastrointestinal hemorrhage.
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopically placed device designed to achieve weight loss and improve glycemic control in obesepatients. Previous studies report promising results but typically included small patient numbers and short follow-up. This study aims to determine the safety and effectiveness of the device. METHODS: Study design: A series of all patients treated by the DJBL at our institutions. OUTCOME MEASUREMENTS: Weight loss, biochemical measures, complications. RESULTS: Between July 2012 and March 2015, 114 consecutive patients were treated for a mean 51.1 weeks (standard deviation (SD) 19.9 weeks). Mean total body weight change from baseline was 12.0 kg (SD 8.5 kg, p < 0.001). Mean percent total body weight loss (%TWL) was 10.5% (SD 7.3%). Mean HbA1c was not significantly improved, but of 10 patients on insulin, 4 ceased insulin and 4 reduced insulin dosages. There was a significant decrease in hemoglobin and total cholesterol and a significant increase in serum alkaline phosphatase. Seventy-four percent of patients experienced at least one adverse event, some of them serious including 6 device obstructions, 5 gastrointestinal hemorrhages, 2 liver abscesses, and 1 acute pancreatitis. Seventy-four percent of patients experienced weight gain after removal with a mean 4.5 ± 6.1 kg (p < 0.0001) within the first 6 months after explantation. CONCLUSIONS: The DJBL provides significant but highly variable weight loss. Glycemic control was variable. Most insulin-requiring T2DM patients ceased or reduced insulin. Most patients experience an adverse event and most regain significant weight after device removal. Major adverse events can occur, including the potentially life-threatening complications of hepatic abscess and gastrointestinal hemorrhage.
Authors: Eduardo G H de Moura; Bruno C Martins; Guilherme S Lopes; Ivan R Orso; Suzana L de Oliveira; Manoel P Galvão Neto; Marco A Santo; Paulo Sakai; Almino C Ramos; Arthur B Garrido Júnior; Marcio C Mancini; Alfredo Halpern; Ivan Cecconello Journal: Diabetes Technol Ther Date: 2011-09-20 Impact factor: 6.118
Authors: Parviez Koehestanie; Charlotte de Jonge; Frits J Berends; Ignace M Janssen; Nicole D Bouvy; Jan Willem M Greve Journal: Ann Surg Date: 2014-12 Impact factor: 12.969
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: Ruben Schouten; Carianne S Rijs; Nicole D Bouvy; Wim Hameeteman; Ger H Koek; Ignace M C Janssen; Jan-Willem M Greve Journal: Ann Surg Date: 2010-02 Impact factor: 12.969
Authors: Barham K Abu Dayyeh; Nitin Kumar; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Michael Larsen; Shelby Sullivan; Christopher C Thompson; Subhas Banerjee Journal: Gastrointest Endosc Date: 2015-07-29 Impact factor: 9.427
Authors: Thomas Karlas; David Petroff; Jürgen Feisthammel; Sebastian Beer; Matthias Blüher; Tatjana Schütz; Ralf Lichtinghagen; Albrecht Hoffmeister; Johannes Wiegand Journal: Obes Surg Date: 2022-06-17 Impact factor: 3.479
Authors: Aruchuna Ruban; Alexander D Miras; Michael A Glaysher; Anthony P Goldstone; Christina G Prechtl; Nicholas Johnson; Navpreet Chhina; Werd Al-Najim; Madhawi Aldhwayan; Natalia Klimowska-Nassar; Claire Smith; Joanne Lord; Jia V Li; Lilliam Flores; Moaz Al-Lababidi; Georgios K Dimitriadis; Mayank Patel; Michael Moore; Harvinder Chahal; Ahmed R Ahmed; Jonathan Cousins; Ghadah Aldubaikhi; Ben Glover; Emanuela Falaschetti; Hutan Ashrafian; Carel W le Roux; Ara Darzi; James P Byrne; Julian P Teare Journal: Ann Surg Date: 2022-03-01 Impact factor: 13.787
Authors: Jan Král; Evžen Machytka; Veronika Horká; Jana Selucká; Filip Doleček; Julius Špičák; Viktorie Kovářová; Martin Haluzík; Marek Bužga Journal: Nutrients Date: 2021-11-26 Impact factor: 5.717